Reading biotech hiring demand in the news — four signals from 17 issues this summer and autumn

Job ads alone rarely tell you why a role is becoming more important. But group the news by role and patterns appear. I re-read the 17 issues and 51 stories BIO:ON Insight covered from June to September 2026 and pulled out four signals that came up again and again.

I'm still a student learning the industry, so this isn't hiring data or an expert forecast — it's the patterns I noticed while writing up the news. Always check each company's careers page for actual openings.

1. The battleground moves to where drugs are made — CMC & quality

• Ultragenyx's Sanfilippo syndrome gene therapy Fayuvi was rejected once over manufacturing, then approved after fixes. (Issue #17)
• A batch of Fresenius's biosimilar was recalled over glass particles in the vials. (Issue #12)

How to read it: As more hard-to-make drugs like gene therapies arrive, proof that a drug can be made to the same quality every time is deciding approval and supply as much as efficacy.

What to prepare: GMP basics, the ideas of deviations and CAPA, and one example of why CMC affects approval.

2. Good drugs don't always get prescribed — Market access

• Lilly's oral obesity drug Foundayo got off to a slower start than its competitor, and coverage from the three biggest US PBMs only began in June, about two months after launch. (Issue #8, Issue #9)
• Later, amid an oral GLP-1 price war, Foundayo cut its cash price and took one in three new prescriptions. (Issue #18)
• With ultra-expensive drugs like a $3.95M gene therapy, how to justify the price and who pays keeps coming up. (Issue #17)

How to read it: After the science wins, the next fight is over coverage, price and channels.

What to prepare: The big picture of reimbursement, the idea of cost-effectiveness (ICER), and an example that answers "why isn't this good drug selling?"

3. Regulatory decisions get more transparent — and more nuanced — Regulatory affairs

• The FDA resumed publishing complete response letters (CRLs), making it harder for companies to spin rejections. (Issue #9)
• Twice-rejected oncolytic virus RP1 turned an advisory committee vote around with real-world data. (Issue #11)
• The FDA approved camizestrant despite a negative advisory vote, while in the same week ivonescimab strengthened its case with final OS data. (Issue #16)

How to read it: Approval isn't a simple pass/fail. It depends on the type and strength of evidence and on dialogue with regulators — and the more that's made public, the more regulatory communication matters.

What to prepare: Practise explaining CRLs, advisory committees and surrogate endpoints vs OS with an example each. The RA filter in the interview question bank helps.

4. People who read the structure behind the headline number — BD

• The Lilly × InnoCare deal was worth up to $3.35B, but only about 3% was guaranteed. (Issue #18)
• Roche paid $190M upfront, with up to $2.3B more in milestones, for Hanmi's 'muscle-sparing' obesity candidate HM17321. (Issue #14)
• Big acquisitions like GSK's ($10.6B) and AbbVie's ($10.9B) were strategies to fill the patent cliff. (Issue #3, Issue #7)

How to read it: Deals keep getting bigger and more frequent, but the yardstick for value is the upfront, milestone and royalty structure — not the total. Korean companies are increasingly the ones being licensed or acquired.

What to prepare: The difference between bio-dollars and guaranteed upfront, the patent cliff, and practice explaining one recent deal by its structure.

The one thing all four share

All four signals come down to the ability to read behind the headline. If you can take one story and talk through fact → interpretation → your role, it should help in an interview for any role. The method is in my three-step interview answer guide.

I'll keep noting new patterns as I write the newsletter every Tuesday.

Sources

1. Fayuvi: Ultragenyx — CRL for UX111 (CMC-related, July 2025), BioSpace — approval and $3.95M price
2. Fresenius recall: FDA recall notice
3. Foundayo: Fierce Pharma — early prescriptions, Eli Lilly — coverage by the three biggest PBMs, CNBC — one in three new oral GLP-1 patients (Sep 21, 2026)
4. FDA CRL publication: FDA — radical transparency, publishing CRLs, BioSpace — pause and resumption
5. RP1 advisory committee (10–3 in favour): Replimune announcement
6. Camizestrant: FDA approval notice; ivonescimab OS: BioSpace
7. Lilly × InnoCare: Fierce Biotech
8. Roche × Hanmi: BioSpace
9. GSK × Nuvalent ($10.6B): GSK press release; AbbVie × Apogee ($10.9B): AbbVie press release